CAMBRIDGE, Mass., Oct. 29, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it has met pre-specified criteria to expand both arms of its ongoing Phase 2 clinical trial evaluating IPI-504 (retaspimycin hydrochloride), its lead heat shock protein 90 (Hsp90) inhibitor, in patients with advanced non-small cell lung cancer (NSCLC).
